About Mark McKenna
Mark McKenna is a director at Apogee Therapeutics.
Form D filings name Mark McKenna as an executive officer and director at Mirador Therapeutics.
Mark McKenna reports to the SEC as a director or officer of 8 public companies, including Freenome (FRNM), Spyre Therapeutics (SYRE) and Helix Acquisition Corp. III (HLXC).
Mark McKenna first appears on SEC filings in 2018.
Experience
This experience comes from SEC filings. The years are when the filings name Mark McKenna in the role, so the role may have started earlier or lasted longer.
AI
Apogee Therapeutics, Inc.
Director
2023 – 2026 · Public company (APGE)
FI
Freenome, Inc.
Director
2024 – 2026 · Public company (FRNM)
SI
Spyre Therapeutics, Inc.
Director
2024 – 2026 · Public company (SYRE)
HI
Helix Acquisition Corp. III
Director
2026 · Public company (HLXC)
NV
NewAmsterdam Pharma Co N.V.
Director
2024 – 2026 · Public company (NAMS)
BI
BridgeBio Oncology Therapeutics, Inc.
Director
2024 – 2025 · Public company (BBOT)
PI
Prometheus Biosciences, Inc.
Chairman, President and CEO
2021 – 2023 · Public company (RXDX)
BI
Bausch Health Companies Inc.
President, Salix
2018 – 2019 · Public company (BHC)
Key Colleagues at Startups
The people Mark McKenna works with at each company, as listed on that company's latest Form D.
Mirador Therapeutics, Inc. · Form D, Apr 3, 2024
PB
Paul Berns
Director
JP
Joseph Papa
Director
SG
Scott Glenn
Director
KB
Kristina Burow
Director
VB
Vika Brough
Executive officer
DD
David Bonita, M.D.
Director
TA
Timothy Andrews
Secretary